FDA Fast Track Puts Erasca's (ERAS) Pancreatic Bet Center Stage
On August 24, Erasca (NASDAQ:ERAS) announced that the FDA had granted Fast Track Designation to ERAS-0015, its oral pan-RAS molecular glue, for patients with metastatic pancreatic adenocarcinoma.








